~~<i id='BD61327A8B'><strike id='BD61327A8B'><tt id='BD61327A8B'><pre id='BD61327A8B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

explore

author：entertainment 2025-09-28 08:32:49 - browse：725

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： PBM executives asked to testify by House panel

Wikipedia

explore

focus

hotspot

focus

Wikipedia

OutgoingBristolCEOGiovanniCaforioEmiliePickeringforSTATIt’schangingoftheguardtimeatpharmaceuticalgia

WSS

CDC recommends rationing of RSV shot due to shortages

The pink breast cancer awareness ribbon needs a redesign

The FDA weighs the risks of candy

Readout Newsletter: XBI biotech index, Akero Therapeutics

The effects of a landmark ruling on DNA ownership are becoming clearer

HHS's proposed rule does nothing to address the climate crisis

knowledge

explore

Wikipedia

Medical records are filled with copy

Warren pushes Witty on UnitedHealth's control over physicians

Apple is now the first public company to be valued at $3 trillion

Emergency medicine has repudiated 'excited delirium.' Now what?

Continuity nursing helped my family in our darkest PICU moments

Brain MRIs reveal impact of 'toxic stress' on Black children

Moonlake's readout produced a cash windfall. Risks remain

Senate panel to vote on hospitals, PBMs, prisoner care

In Memoriam: Notable people who died in 2023

Welsh Carson private equity firm escapes from FTC antitrust case

explore

Telehealth options flood the market as retailers push virtual care

Senate panel to vote on hospitals, PBMs, prisoner care

Telehealth options flood the market as retailers push virtual care

Readout Newsletter: XBI biotech index, Akero Therapeutics

Meta's Zuckerberg and Chan on track to put $50 billion into science

Maker of FluMist seeks to allow at

focus

hotspot

focus

Wikipedia